Business Context and Reporting Period
This Form 6-K filing is submitted by Galapagos NV (not Lakefront Biotherapeutics NV as indicated in metadata) for the month of September 2018. The registrant is a foreign private issuer incorporated in Belgium, with its principal executive office in Mechelen. The filing serves to incorporate by reference a press release dated September 13, 2018 (Exhibit 99.1), into the company's Registration Statements on Forms F-3 and S-8.
Financial Metrics
The provided filing text contains no financial data. It is a procedural filing referencing an external press release. Consequently, there are no reported values for revenue, profit, cash flow, margins, debt, or liquidity within this document.
Material Changes
The filing does not disclose specific material changes to financial performance or operations. It solely announces the issuance of a press release on September 13, 2018. The content of that press release is not included in the text provided, only the fact of its issuance and incorporation by reference.
Guidance, Outlook, and Risks
The text does not contain management commentary, financial guidance, outlook, or specific risk factors. It notes that the press release includes quotes from Dr. Malte Peters and Dr. Walid Abi-Saab, but the substance of these quotes is not present in the filing text. No unusual items or contingencies are described in the provided content.
Key Facts for Investor Verification
- Company Identity: Verify that the filing pertains to Galapagos NV, not Lakefront Biotherapeutics NV.
- Missing Content: The actual details of the September 13, 2018, press release (Exhibit 99.1) are not included in this text; investors must locate the full exhibit to understand the material event.
- Financial Data: No financial metrics are available in this specific filing; refer to the company's Form 20-F or quarterly reports for financial performance.
- Registration Statements: The press release is incorporated into multiple active registration statements (Forms F-3 and S-8), indicating potential capital market activity.